TY - JOUR T1 - Genetic regulation of <em>OAS1</em> nonsense-mediated decay underlies association with risk of severe COVID-19 JF - medRxiv DO - 10.1101/2021.07.09.21260221 SP - 2021.07.09.21260221 AU - A Rouf Banday AU - Megan L Stanifer AU - Oscar Florez-Vargas AU - Olusegun O Onabajo AU - Muhammad A Zahoor AU - Brenen W Papenberg AU - Timothy J Ring AU - Chia-Han Lee AU - Evangelos Andreakos AU - Evgeny Arons AU - Greg Barsh AU - Leslie G Biesecker AU - David L Boyle AU - Andrea Burnett-Hartman AU - Mary Carrington AU - Euijin Chang AU - Pyoeng Gyun Choe AU - Rex L Chrisholm AU - Clifton Dalgard AU - Jeff Edberg AU - Nathan Erdmann AU - Heather S Feigelson AU - Gary S Firestein AU - Adam J Gehring AU - Michelle Ho AU - Steven Holland AU - Amy A Hutchinson AU - Hogune Im AU - Michael G Ison AU - Hong Bin Kim AU - Robert J Kreitman AU - Bruce R Korf AU - Lisa Mirabello AU - Jennifer A Pacheco AU - Michael J Peluso AU - Daniel J Rader AU - David T Redden AU - Marylyn D Ritchie AU - Brooke Rosenbloom AU - Hanaisa P Sant Anna AU - Sharon Savage AU - Eleni Siouti AU - Vasiliki Triantafyllia AU - Joselin M Vargas AU - Anurag Verma AU - Vibha Vij AU - Duane R Wesemann AU - Meredith Yeager AU - Xu Yu AU - Yu Zhang AU - Steeve Boulant AU - Stephen J Chanock AU - Jordan J Feld AU - Ludmila Prokunina-Olsson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/13/2021.07.09.21260221.abstract N2 - Genomic regions have been associated with COVID-19 susceptibility and outcomes, including the chr12q24.13 locus encoding antiviral proteins OAS1-3. Here, we report genetic, functional, and clinical insights into genetic associations within this locus. In Europeans, the risk of hospitalized vs. non-hospitalized COVID-19 was associated with a single 19Kb-haplotype comprised of 76 OAS1 variants included in a 95% credible set within a large genomic fragment introgressed from Neandertals. The risk haplotype was also associated with impaired spontaneous but not treatment-induced SARS-CoV-2 clearance in a clinical trial with pegIFN-λ1. We demonstrate that two exonic variants, rs10774671 and rs1131454, affect splicing and nonsense-mediated decay of OAS1. We suggest that genetically-regulated loss of OAS1 expression contributes to impaired spontaneous clearance of SARS-CoV-2 and elevated risk of hospitalization for COVID-19. Our results provide the rationale for further clinical studies using interferons to compensate for impaired spontaneous SARS-CoV-2 clearance, particularly in carriers of the OAS1 risk haplotypes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04354259Funding StatementThe results are partially based on data generated by the TCGA Research Network. We used data provided by the Kaiser Permanente Research Bank (KPRB) from the KPRB collection, which includes the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH), funded by the National Institutes of Health (RC2 AG036607), the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, The Ellison Medical Foundation, and the Kaiser Permanente Community Benefits Program. Access to data used in this study may be obtained by application to the KPRB at kp.org/researchbank/researchers. Research reported in this publication was supported by the Intramural Research Programs of the National Cancer Institute: Division of Cancer Epidemiology and Genetics and Center for Cancer Research, Frederick National Laboratory for Cancer Research, contract number HHSN261200800001E; National Center for Advancing Translational Science of the National Institutes of Health under award number UL1TR003096 associated with the University of Alabama at Birmingham COVID-19 Enterprise Study IRB 20005127, NHGRI Intramural Research Program grants HG200388 07 and HG200359 12. Additional funding was provided by the state of Alabama through the Alabama Genomic Health Initiative (IRB F170303004). MLS was supported by grants: DFG (416072091) and the BMBF (01KI20239B). SB was supported by Deutsche Forschungsgemeinschaft (DFG): project numbers 415089553 (Heisenberg program), 240245660 (SFB1129), and 272983813 (TRR179), the state of Baden Wuerttemberg (AZ: 33.7533.6 21/5/1) and the Bundesministerium Bildung und Forschung (BMBF) (01KI20198A). EA was supported by research grants from the European Commission IMMUNAID (779295) and CURE (767015) and the Hellenic Foundation for Research and Innovation INTERFLU (1574). HBK was supported by grant no 02-2020-012 from the SNUBH Research Fund. The pegIFNλ1 clinical trial was supported by the Toronto COVID19 Action Initiative (72059280), the Ontario Together COVID19 Research Application (C224 2428560 FELD) and the Canadian Institutes for Health Research (VR3-172648). Support for title page creation and format was provided by AuthorArranger (https://authorarranger.nci.nih.gov/), a tool developed at the NCI. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views and policies of the National Institutes of Health or Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All contributing studies obtained IRB approvals from corresponding institutions. Ethical approval of the clinical trial NCT04354259 was done under a Clinical Trial Application approved by Health Canada. Studies contributing to COVNET: University of Alabama, IRB F170303004, Penn Medicine BioBank, IRB 813913, Seoul National University College of Medicine/Seoul National University Hospital IRB H-2011-034-1169, "Northwestern University, NUGene: Gene-Disease Associations and Treatment Outcomes STU00010003, NHGRI, 20-HG-0090 NIH received only de-identified information from each study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics for all genetic analyses is provided in Supplementary Tables. Individual genotypes will be submitted to dbGAP. Dataset for Oxford Nanopore RNA-seq was deposited to NCI SRA as BioProject PRJNA743928. Full-length sequence data for OAS1-p42 transcript with Short exon 3 was deposited to NCBI GenBank with accession number MZ491787. Requests for any additional data or reagents should be addressed to L.P.-O. (prokuninal@mail.nih.gov). ER -